Lupeng Pharmaceutical

Lupeng Pharmaceutical was founded in June 2018 in Guangzhou. The company focuses on the research and development of innovative drugs for malignant tumors, autoimmune diseases, and hepatitis B virus, which seriously affect human health. It has a world-class drug design and clinical development team, concentrating on challenging target designs, new drug resistance mutations, or targets where existing drugs have significant shortcomings. The company emphasizes the development of targets with strong synergistic effects related to its core projects (BTK, Bcl-2, Bcl-xl). Lupeng Pharmaceutical's R&D pipeline includes over 10 projects, among which the core projects LP-168, LP-108, and LP-118 possess world-class competitiveness, targeting the global market. Clinical trials are currently being conducted in China, the United States, and Europe. Since its establishment, the company has continuously received investments and support from multiple international and domestic biopharmaceutical venture capital funds. Upholding the philosophy of "Diligence, Pragmatism, Innovation, and Service to Humanity," Lupeng Pharmaceutical is committed to building a multinational pharmaceutical enterprise that integrates R&D, production, and sales, with a high level of innovation and social responsibility, headquartered in the Greater Bay Area.